• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Legend Biotech Corp ADR (NQ: LEGN )

    45.02 +0.75 (+1.69%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Legend Biotech Corp ADR

    < Previous 1 2 3 4 5 6 Next >
    9 Analysts Have This To Say About Legend Biotech
    Via Benzinga
    Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients
    Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by... 
    Via Benzinga
    Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma
    Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma. 
    Via Investor's Business Daily
    Where Legend Biotech Stands With Analysts
    Via Benzinga
    Peering Into Legend Biotech's Recent Short Interest
    Via Benzinga
    Beyond The Numbers: 14 Analysts Discuss Legend Biotech Stock
    Via Benzinga
    Looking Into Legend Biotech's Recent Short Interest
    Via Benzinga
    Beyond The Numbers: 15 Analysts Discuss Legend Biotech Stock
    Via Benzinga
    The Latest Analyst Ratings For Legend Biotech
    Via Benzinga
    Assessing Legend Biotech: Insights From 15 Financial Analysts
    Via Benzinga
    LEGN Stock Earnings: Legend Biotech Beats EPS, Beats Revenue for Q2 2024
    LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    Will Genscript Cash Out Of Legend Biotech In The Face Of Fat Profit Temptation?
    Key Takeaways: Analysts expect annual sales of Carvykti, Legend Biotech’s core cancer therapy, to peak at $7.3 billion With about $2 billion in cash reserves, Genscript isn’t under pressure to sell its... 
    Via Benzinga
    Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
    Top performers last week: $WBD up 18.28%, $MSTR up 16.74%, $DHI up 12.91%, $COIN up 12.39%, $OQL up 7.89%, $UNH up 7.84%, $STT up 7.21%, $LEN up 7.07%, $TOST up 7.05%, $EPAM up 6.97%. Are they in your... 
    Via Benzinga
    Week In Review: Korea's SK Biopharma Acquires Radiopharmaceutical In $571 Million Deal
    In recent news, South Korea’s SK Biopharma in-licensed global rights to a radiopharmaceutical compound developed by Full-Life Technologies of Shanghai in a $571 million deal. 
    Via Talk Markets
    Unveiling 18 Analyst Insights On Legend Biotech
    Via Benzinga
    Legend Biotech Stock: A Deep Dive Into Analyst Perspectives (14 Ratings)
    Via Benzinga
    Analyst Ratings For Legend Biotech
    Via Benzinga
    Unveiling 9 Analyst Insights On Legend Biotech
    Via Benzinga
    Cintas Posts Upbeat Earnings, Joins CommScope Holding, Virtu Financial And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
    Johnson & Johnson announced Phase 3 CARTITUDE-4 study results showing Carvykti significantly improves overall survival in relapsed or lenalidomide-refractory multiple myeloma after one prior line of... 
    Via Benzinga
    Legend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: Analyst
    Legend Biotech analyst predicts growth for Carvykti. The Multiple Myeloma drug could become a $5B+ product. 
    Via Benzinga
    Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
    Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
    Via Benzinga
    Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
    In the last three months, IBRX outperformed NVDA by over 3x. 
    Via Talk Markets
    LEGN Stock Earnings: Legend Biotech Beats EPS, Misses Revenue for Q1 2024
    LEGN stock results show that Legend Biotech beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
    Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
    Via Benzinga
    Exposures Product Safety
    Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
    FDA approves Johnson & Johnson's Carvykti, a BCMA-targeted therapy for relapsed or refractory multiple myeloma patients, offering hope with increased manufacturing capacity and extended collaboration... 
    Via Benzinga
    Exposures Product Safety
    GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
    Key Takeaways: GenScript’s cell therapy revenue grew by 143.7% last year as a CAR-T cell therapy developed by its Legend Biotech subsidiary gained traction Legend’s Carvykti is expected to hit annual... 
    Via Benzinga
    FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
    FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... 
    Via Benzinga
    Exposures Product Safety
    FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
    Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into... 
    Via Benzinga
    Exposures Product Safety
    Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
    U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.